

Edinburgh, 7 October 2019

MedAnnex begins cell line development at FUJIFILM Diosynth

Edinburgh-based biotechnology company MedAnnex today announced that cell line development for the generation of its anti-Annexin A1 antibodies is under way, at FUJIFILM Diosynth Biotechnologies' (Fujifilm) Billingham, UK site.

MedAnnex's novel antibodies are being developed as potentially ground-breaking therapies for autoimmune diseases and other medical conditions. The cell line development, via Fujifilm's Apollo™X advanced expression technology, is part-funded by Scottish Enterprise's SMART: SCOTLAND R&D awards scheme.

The initiation of this production process follows a recent Series B investment of £11 million for MedAnnex to accelerate its therapeutic antibody development programme towards clinical trials.

Dr Fiona Dempsey, Director of Scientific Operations at MedAnnex, said: "We're delighted to be taking this significant step on our journey towards the clinic, and to be moving closer to our goal of providing new treatments to help patients and their families."

Dr. Fay Saunders, Head of Upstream Mammalian Cell Culture, Process Development of Fujifilm said "We are very happy to be working with MedAnnex in the expression of their anti-Annexin A1 antibody using our Apollo X advanced expression system."

- ENDS -

About MedAnnex Ltd: MedAnnex Ltd is a privately-owned company founded by UK biotechnology entrepreneur Professor Chris Wood. The company has developed novel antibodies to specifically modulate the innate and adaptive immune systems to treat autoimmune disorders and various other serious diseases. MedAnnex is working with internationally renowned experts at leading UK universities including Professors David Isenberg and Claudia Mauri (University College London), Professor Carl Goodyear (University of Glasgow) and Professor Chris Parris (Anglia Ruskin University). For more information, visit: www.medannex.org

About FUJIFILM Diosynth Biotechnologies: FUJIFILM Diosynth Biotechnologies (Fujifilm) is an industry-leading Biologics Contract Development and Manufacturing Organisation (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. Fujifilm has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ X cell line systems to process development, analytical development, clinical and commercial manufacturing. For more information, visit: www.fujifilmdiosynth.com

MedAnnex Ltd press enquiries – email jamesingham@medannex.org